Nature Biotechnology Podcast show

Nature Biotechnology Podcast

Summary: Nature Biotechnology podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.

Join Now to Subscribe to this Podcast

Podcasts:

 First Rounder: Jeff Leiden | File Type: audio/mpeg | Duration: 1:09

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.

 First Rounder: Jeff Leiden | File Type: audio/mpeg | Duration: 1:09:00

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.

 First Rounder: Susan Windham-Bannister | File Type: audio/mpeg | Duration: 1:07

Susan Windham-Bannister is president and CEO of Biomedical Growth Strategies and was the founding president and CEO of the Massachusetts Life Sciences Center (MLSC). Her conversation with Nature Biotechnology covers her childhood in segregated St. Louis, her work at MLSC helping grow the life sciences sector in Massachusetts through Governor Deval Patrick's $1-billion initiative, and race relations in Boston and the United States.

 First Rounder: Susan Windham-Bannister | File Type: audio/mpeg | Duration: 1:07:00

Susan Windham-Bannister is president and CEO of Biomedical Growth Strategies and was the founding president and CEO of the Massachusetts Life Sciences Center (MLSC). Her conversation with Nature Biotechnology covers her childhood in segregated St. Louis, her work at MLSC helping grow the life sciences sector in Massachusetts through Governor Deval Patrick's $1-billion initiative, and race relations in Boston and the United States.

 First Rounder: Stelios Papadopoulos | File Type: audio/mpeg | Duration: 1:04:02

Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.

 First Rounder: Stelios Papadopoulos | File Type: audio/mpeg | Duration: 1:04:02

Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.

 First Rounder: Greg Winter | File Type: audio/mpeg | Duration: 1:22:18

Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.

 First Rounder: Greg Winter | File Type: audio/mpeg | Duration: 1:22:18

Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.

 First Rounder: Jan Vilcek | File Type: audio/mpeg | Duration: 1:05:25

Jan is the co-founder, CEO and chairman of the Vilcek Foundation, and also a long-time researcher and professor at New York University's School of Medicine. His conversation with Nature Biotechnology covers his harrowing childhood in Czechoslovakia during the rise of Nazi Germany and World War II, his escape from communist Czechoslovakia through defection, and his role in the discovery of the blockbuster drug Remicade.

 First Rounder: Jan Vilcek | File Type: audio/mpeg | Duration: 1:05:25

Jan is the co-founder, CEO and chairman of the Vilcek Foundation, and also a long-time researcher and professor at New York University's School of Medicine. His conversation with Nature Biotechnology covers his harrowing childhood in Czechoslovakia during the rise of Nazi Germany and World War II, his escape from communist Czechoslovakia through defection, and his role in the discovery of the blockbuster drug Remicade.

 First Rounder: Rachel Haurwitz | File Type: audio/mpeg | Duration: 44:07

Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.

 First Rounder: Rachel Haurwitz | File Type: audio/mpeg | Duration: 44:07

Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.

 First Rounder: Stephen Quake | File Type: audio/mpeg | Duration: 56:58

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced.

 First Rounder: Stephen Quake | File Type: audio/mpeg | Duration: 56:58

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced.

 First Rounder: Jeremy Levin | File Type: audio/mpeg | Duration: 1:35:18

Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results.

Comments

Login or signup comment.